| Atrial Fibrillation
Eliquis vs Multaq
Side-by-side clinical, coverage, and cost comparison for atrial fibrillation.Deep comparison between: Eliquis vs Multaq with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsMultaq has a higher rate of injection site reactions vs Eliquis based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Multaq but not Eliquis, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Eliquis
Multaq
At A Glance
Oral
Twice daily
Factor Xa inhibitor
Oral
Twice daily
Multi-class antiarrhythmic
Indications
- Atrial Fibrillation
- Deep Vein Thrombosis
- Pulmonary Embolism
- Venous Thromboembolism
- Atrial Fibrillation
Dosing
Atrial Fibrillation 5 mg orally twice daily; 2.5 mg twice daily in patients with at least 2 of the following: age >=80 years, body weight <=60 kg, or serum creatinine >=1.5 mg/dL.
Deep Vein Thrombosis (prophylaxis, hip or knee replacement) 2.5 mg orally twice daily initiated 12-24 hours post-surgery; 35 days for hip replacement, 12 days for knee replacement.
Deep Vein Thrombosis, Pulmonary Embolism (treatment) 10 mg orally twice daily for 7 days, then 5 mg twice daily.
Deep Vein Thrombosis, Pulmonary Embolism (recurrence reduction) 2.5 mg orally twice daily after at least 6 months of treatment for DVT or PE.
Venous Thromboembolism (pediatric) Weight-based dosing orally twice daily following at least 5 days of initial anticoagulant treatment; doses range from 0.3 mg to 10 mg twice daily based on weight tier.
Atrial Fibrillation 400 mg twice daily orally; one tablet with the morning meal and one tablet with the evening meal.
Contraindications
- Active pathological bleeding
- Severe hypersensitivity reaction to apixaban (e.g., anaphylactic reactions)
- Permanent atrial fibrillation (patients in whom normal sinus rhythm will not or cannot be restored)
- Symptomatic heart failure with recent decompensation requiring hospitalization or NYHA Class IV symptoms
- Second or third-degree atrioventricular (AV) block, or sick sinus syndrome (except when used in conjunction with a functioning pacemaker)
- Bradycardia
- Concomitant use of strong CYP3A inhibitors (ketoconazole, itraconazole, voriconazole, cyclosporine, telithromycin, clarithromycin, nefazodone, ritonavir)
- Concomitant use of erythromycin
- Concomitant use of QT-prolonging drugs or herbal products (phenothiazine antipsychotics, tricyclic antidepressants, certain oral macrolide antibiotics, Class I and III antiarrhythmics)
- Liver or lung toxicity related to previous use of amiodarone
- QTc interval >500 ms or PR interval >280 ms
- Severe hepatic impairment
- Hypersensitivity to the active substance or to any of the excipients
Adverse Reactions
Most common (>=1%) Epistaxis, contusion, hematuria, menorrhagia, hematoma, hemoptysis, rectal hemorrhage, gingival bleeding, nausea, anemia.
Serious Major bleeding including intracranial hemorrhage, gastrointestinal bleeding, and fatal bleeding.
Most common (>=1%) Diarrhea, nausea, abdominal pain, vomiting, dyspepsia, asthenia, bradycardia, skin rash
Serious New or worsening heart failure, liver injury, pulmonary toxicity, QT prolongation, hypokalemia and hypomagnesemia with potassium-depleting diuretics
Postmarketing New or worsening heart failure, atrial flutter with 1:1 AV conduction, liver injury, interstitial lung disease (pneumonitis, pulmonary fibrosis), anaphylactic reactions including angioedema, vasculitis including leukocytoclastic vasculitis
Pharmacology
Apixaban is a selective inhibitor of factor Xa (FXa) that does not require antithrombin III for antithrombotic activity; by inhibiting free and clot-bound FXa and prothrombinase activity, it decreases thrombin generation and thrombus development without directly affecting platelet aggregation.
Dronedarone is an antiarrhythmic agent with properties belonging to all four Vaughan-Williams classes (I, II, III, and IV), though the mechanism of action and contribution of each class to the clinical effect is unknown; it also acts as a moderate inhibitor of CYP3A and CYP2D6 and inhibits P-glycoprotein transport.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Eliquis
- Covered on 5 commercial plans
- PA (0/12) · Step Therapy (0/12) · Qty limit (11/12)
Multaq
- Covered on 5 commercial plans
- PA (4/12) · Step Therapy (0/12) · Qty limit (12/12)
UnitedHealthcare
Eliquis
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (8/8)
Multaq
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (0/8) · Qty limit (3/8)
Humana
Eliquis
- Covered on 0 commercial plans
- PA (0/3) · Step Therapy (0/3) · Qty limit (2/3)
Multaq
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Eliquis.
No savings programs available for Multaq.
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
EliquisView full Eliquis profile
MultaqView full Multaq profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.